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Abstract 64 
Background: Although sensitizer-induced occupational asthma (OA) accounts for an 65 
appreciable fraction of adult asthma, the severity of OA has received little attention.  66 
Objective: The aim of this study was to characterize the burden and determinants of 67 
severe OA in a large multicenter cohort of subjects with OA. 68 
Methods: This retrospective study included 997 subjects with OA ascertained by a 69 
positive specific inhalation challenge completed in 20 tertiary centers in 11 European 70 
countries during the period 2006-2015. Severe asthma was defined by a high-level of 71 
treatment and any one of the following criteria: 1) daily need for a reliever medication; 2) 72 
two or more severe exacerbations in the previous year; or 3) airflow obstruction. 73 
Results: Overall, 162 (16.2%; 95% CI: 14.0-18.7%) subjects were classified as having 74 
severe OA. Multivariable logistic regression analysis revealed that severe OA was 75 
associated with persistent (vs. reduced) exposure to the causal agent at work (odds ratio 76 
[OR], 2.78 [95% CI: 1.50-5.60]); a longer duration of the disease (OR, 1.04 [1.00-1.07]); a 77 
low level of education (OR, 2.69 [1.73-4.18]); childhood asthma (OR, 2.92 [1.13-7.36]); 78 
and sputum production (OR, 2.86 [1.87-4.38]). In subjects removed from exposure, 79 
severe OA was associated only with sputum production (OR, 3.68 [1.87-7.40]); a low 80 
education level (OR, 3.41 [1.72-6.80]); and obesity (OR, 1.98 [0.97-3.97]). 81 
Conclusions: This study indicates that a substantial proportion of subjects with OA 82 
experience severe asthma and identifies potentially modifiable risk factors for severe OA 83 
that should be targeted in order to reduce the adverse impacts of the disease.  84 
Word count: 249 words  85 
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Highlights Box 86 
What is already known about this topic? 87 
• There is only scarce information on the burden and determinants of severe 88 
sensitizer-induced occupational asthma (OA).   89 
What does this article add to our knowledge? 90 
• This cohort study indicates that a substantial fraction of subjects with OA (16.2%; 91 
95% CI: 14.0-18.7%) experience severe asthma.  92 
• The findings highlight exposure-related and individual risk factors for severe OA.  93 
How does this study impact current management guidelines? 94 
• The findings of this cohort study may assist clinicians and health policy makers 95 
identify potentially modifiable risk factors for severe OA that should be targeted in 96 
strategies aimed at minimizing the health and socioeconomic impacts of the disease.  97 
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List of abbreviations: 98 
 AIC - Akaike information criterion 99 
 ATS - American Thoracic Society 100 
 CI - Confidence interval 101 
 ERS - European Respiratory Society 102 
 FEV1 -Forced expiratory volume in one second 103 
 FVC - Forced vital capacity 104 
 GINA - Global initiative for asthma 105 
 HMW - High-molecular-weight agents 106 
 IQR - Interquartile range 107 
 LMW - Low-molecular-weight agents 108 
 NSBH - nonspecific bronchial hyperresponsiveness 109 
 OA - Occupational asthma 110 
 OR - Odds ratio 111 
 SABA - Short-acting beta2-agonist 112 
 SA - Severe asthma 113 
 SIC - Specific inhalation challenge  114 
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INTRODUCTION 115 
Severe asthma (SA) imposes a substantial public health burden since the condition has a 116 
major impact on patients’ quality of life and accounts for a disproportionately large portion 117 
of health care costs associated with asthma (1, 2). Clinical practice guidelines advocate 118 
the identification and remediation of exposures contributing to asthma severity as a key 119 
step in disease management (1, 3). Among potentially modifiable exposures, the 120 
workplace environment is likely to hold a notable position since workplace exposures to 121 
high-molecular-weight (HMW) and low-molecular-weight (LMW) asthmagenic agents 122 
have been associated with an increased risk of poor asthma control and severe 123 
exacerbations (4, 5).  124 
Sensitizer-induced occupational asthma (OA), a distinguishable phenotype of work-125 
related asthma, is characterized by the de novo inception of asthma or the recurrence of 126 
previously quiescent asthma induced by immunologically-mediated sensitization to a 127 
specific agent at the workplace (6, 7). Enhancing our knowledge of the burden and 128 
determinants of severe OA may be relevant from both clinical and health-economic 129 
perspectives. Complete avoidance of exposure to the causal agent is the recommended 130 
treatment option for OA but is associated with a higher socioeconomic impact as 131 
compared to reduction of exposure (6, 8-11). The severity of asthma at the time of 132 
diagnosis has been consistently identified as a risk factor for a worse outcome after 133 
removal from exposure (6, 8, 12). However, the determinants of OA severity have so far 134 
received little attention (13, 14).  135 
The aim of this study was to estimate the burden of severe OA and to identify its 136 
determinant factors in a large multicenter cohort of subjects with OA confirmed by specific 137 
inhalation challenge (SIC).  138 
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METHODS 139 
Study Design and Population 140 
This retrospective, cross-sectional, observational study was conducted in an international, 141 
multicenter cohort of subjects with OA recruited from 20 tertiary centers in 11 European 142 
countries. Eligible subjects were those with a diagnosis of OA ascertained by a positive 143 
SIC completed between January 2006 and December 2015. From the 1,180 eligible 144 
subjects with a positive SIC, 183 subjects with missing data pertaining to the variables 145 
used for assessing asthma severity and control were excluded form this analysis (Figure 146 
1 and Appendix E1 and in this article’s Online Repository).  147 
Ethics 148 
Each participating center was requested to obtain approval from its local Institutional 149 
Review Board for this analysis of retrospective anonymized data. The central database at 150 
the Strasbourg University was approved by the “Comité Consultatif sur le Traitement de 151 
l’Information en Matière de Recherche dans le Domaine de la Santé” and the 152 
“Commission Nationale de l’Informatique et des Libertés”. 153 
Demographic and Clinical Characteristics 154 
Information on demographic, clinical, occupational, and physiological characteristics of 155 
the subjects at the time of the diagnostic evaluation were entered in a standardized 156 
database in each participating center (see Appendix E1 and in this article’s Online 157 
Repository). The requested data were retrospectively retrieved from medical charts in 10 158 
centers while they had been longitudinally entered in existing local databases in the 159 
remaining centers. 160 
Briefly, the database gathered information on the following items: 1) causal agent and job; 161 
2) demographic characteristics; 3) clinical features; 4) nature and timing of exposure to 162 
the causal agent and work-related respiratory symptoms; 5) co-existing disorders (i.e. 163 
physician-based diagnosis of work-related rhinitis, conjunctivitis, daily sputum production, 164 
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dysphonia, contact urticaria and/or dermatitis, and sinusitis). Investigators were asked to 165 
provide detailed asthma medications used: 1) during the last month of exposure at work 166 
and 2) during the last month before the SIC procedure for those subjects who were no 167 
longer exposed to the causal agent at that time. The frequency of short-acting beta2-168 
agonist (SABA) use was categorized as "never", "once a week or less ", "two or three 169 
times a week", "once or two times per day", or "three or more times a day" similar to the 170 
Asthma Control Test (15). The number of severe exacerbations during: 1) the last 12 171 
months at work and 2), during the last 12 months before the SIC procedure for those 172 
subjects who had been removed from exposure were also collected. The level of 173 
exposure to the causal agent during the last month at work was graded by the 174 
investigators as being “unchanged/persistent” (i.e. similar to the conditions of exposure 175 
that prevailed at the time of asthma onset) or “reduced”. Data on biomarkers of airway 176 
inflammation were not included in this analysis because this information was available for 177 
a limited fraction of the subjects. 178 
Lung Function Assessments 179 
The database collected the baseline prebronchodilator forced vital capacity (FVC) and 180 
forced expiratory volume in 1 sec (FEV1) values measured at the time of the SIC 181 
procedure before challenge exposure to the causal agent. The level of nonspecific 182 
bronchial hyperresponsiveness (NSBH) at baseline and 24 hours after challenge 183 
exposure was recorded and expressed as the concentration or dose of the 184 
pharmacological agent inducing a 15% or 20% fall in FEV1 according to the 185 
bronchoprovocation method used in each center (see Appendix E2 and Table E1 in this 186 
article’s Online Repository).  187 
SICs were performed according to international recommandations pertaining to the 188 
performance of a control (placebo) challenge and the duration of the functional monitoring 189 
after the end of the active challenge exposure (16, 17). For each SIC, the database 190 
requested information on the method used for delivering the suspected occupational 191 
either through a “realistic” approach mimicking the workplace exposure or the inhalation 192 
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of “allergen extract”. More detailed Information on the methodology of SICs is available in 193 
Appendix E3 of this article’s Online Repository.  194 
Asthma Outcomes 195 
Asthma treatment: The intensity of asthma treatment was graded a posteriori according to 196 
the treatment steps proposed by the Global Initiative for Asthma (GINA) (3). High-level 197 
treatment was defined as treatment step 4-5 (i.e. use of a high dose of inhaled 198 
corticosteroid and a second controller or systemic corticosteroid use >50% of the 199 
previous year). 200 
Asthma control: The need for an inhaled SABA for symptom relieve was used as a proxy 201 
for the level of symptom control because most centers did not use validated instruments 202 
for the assessment of asthma control. For the purpose of this study, “poor symptom 203 
control” was therefore defined by the need for a SABA once or more a day as proposed in 204 
the American Thoracic Society (ATS) recommendations issued in 2000 (18).  205 
Exacerbations: Severe exacerbations were defined as those requiring oral corticosteroids 206 
for at least three consecutive days or emergency room visit or hospitalization (19, 20). 207 
Airflow obstruction: Baseline airflow obstruction was defined by a FEV1<80% predicted 208 
value together with a FEV1/FVC ratio <0.70. 209 
Severe asthma: The definition of SA was adapted from the ERS/ATS criteria (1, 3) and 210 
required a high-level treatment (i.e. GINA treatment step 4-5) together with any one of the 211 
following criteria indicating uncontrolled asthma: 1) “poor symptom control”; 2) two or 212 
more severe exacerbations in the previous year; or 3) airflow obstruction.  213 
Data Analysis 214 
Continuous measures were summarized by medians and interquartile ranges (IQR) and 215 
categorical variables by their frequencies and proportions. Comparison between subjects 216 
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with and without severe OA was made using the Fisher’s exact or chi-squared test for 217 
categorical variables and the Wilcoxon rank-sum test for numerical variables. 218 
Multivariable logistic regression analysis was carried out using a binomial generalized 219 
linear model and the best parsimonious models were selected using a stepwise 220 
procedure based on Akaike information criterion (AIC) to identify the clinical and 221 
physiological characteristics that were associated with severe OA. The potential 222 
explanatory variables incorporated into these regressions are detailed in Appendix E4 in 223 
this article’s Online Repository. Additional multivariable logistic regression analyses were 224 
conducted in order to investigate the variables associated with each of the domains used 225 
to define SA: high-intensity treatment; poor symptom control; ≥2 severe exacerbations 226 
during the last 12 months at work; and airflow obstruction measured at the time of the SIC 227 
procedure (see Appendix E4 in this article’s Online Repository). 228 
In subjects who were removed from exposure at the time of the diagnostic evaluation 229 
(n=467), the components of asthma severity at this time point were compared to those 230 
recorded when the subjects were still exposed at work. A multivariable logistic regression 231 
was also used to identify the clinical and physiological characteristics that were 232 
associated with severe asthma at the time of the SIC. Missing values were not imputed 233 
and subjects with missing data were not incorporated in multivariable analyses. Statistical 234 
analysis was performed using the R software version 3.4.1 (https://cran.r-project.org). A 235 
P-value <0.05 was considered significant.  236 
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RESULTS 237 
Population 238 
The population included 997 patients with OA ascertained by a positive SIC result (see 239 
Appendix E1 and Figure E1 in this article’s Online Repository). The demographic, clinical, 240 
and functional characteristics of the cohort are presented in Tables I and II. The 241 
occupational agents that induced a positive SIC response are summarized in Table E2 of 242 
in this article’s Online Repository.  243 
Severe Occupational Asthma While at Work 244 
The prevalence rates of high-level treatment, poor symptom control, ≥2 severe asthma 245 
exacerbations during the last 12 months of exposure at work, and airflow obstruction were 246 
30.3%, 30.2%, 8.7%, and 11.9%, respectively (Tables I and II). Overall, 162 (16.2%; 95% 247 
confidence interval [CI]: 14.0-18.7) subjects were categorized as having severe OA. 248 
Multivariable logistic regression analysis revealed that severe OA while at work was 249 
associated with “unchanged/persistent” (vs. reduced) exposure to the causal agent at 250 
work (odds ratio [OR], 2.78 [95% CI: 1.50-5.60], P = 0.002) and a longer duration of work-251 
related symptoms prior to SIC (OR: 1.04 [1.00-1.07] for every 12-month period of 252 
symptomatic exposure, P = 0.036) (Table III). There were also significant and 253 
independent associations between severe OA and a low level of education (i.e., ≤6 years 254 
of school attendance) (OR, 2.69 [1.73-4.18], P < 0.001); a history of childhood asthma 255 
(i.e., ≤12 years) (OR, 2.92 [1.13-7.36], P = 0.024); daily sputum production (OR, 2.86 256 
[1.87-4.38], P <0.001); and dysphonia at work (OR, 1.81 [1.00-3.18], P = 0.043). Subjects 257 
with severe OA were 2.5 times more likely (OR, 2.50 [1.16-7.08]; P = 0.040) to have been 258 
investigated in centers with a “high SIC activity” (i.e. >4 positive SIC per year). 259 
The multivariable logistic regression models for each dimension of severe OA while 260 
exposed at work (i.e. high-intensity treatment; poor symptom control; ≥2 severe 261 
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exacerbations during the last 12 months at work; and airflow obstruction) are summarized 262 
in Table IV.  263 
Asthma Severity in Subjects Removed From Exposure 264 
At the time of the SIC procedure, 467 (46.8%) subjects had already been removed from 265 
exposure to the causal agent for a median duration of 7.0 (3.0-13.0) months. The rates of 266 
poor symptom control and exacerbations were significantly reduced at the time of the SIC 267 
while the intensity of treatment remained unchanged (Table V). Overall, the proportion of 268 
subjects with severe asthma was 18.0% when the subjects were exposed at work and 269 
decreased to 11.1% (p=0.004) when the subjects were removed from exposure at the 270 
time of SIC. In these subjects, a multivariable analysis showed that SA after removal from 271 
exposure was only associated with daily sputum production (OR, 3.68 [1.87-7.40], P < 272 
0.001); a low level of education (OR, 3.41 [1.72-6.80], P < 0.001); and a body mass index 273 
≥30 kg/m2 (OR, 1.98 [0.97-3.97], P = 0.056).  274 
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DISCUSSION 275 
Prevalence of Severe Occupational Asthma 276 
This cohort study indicates that a substantial fraction of subjects with OA (16.2%; 95% CI: 277 
14.0-18.7%) experience SA according to the multidimensional ERS/ATS consensus 278 
definition of the disease (1). This estimate is higher than those found in the general adult 279 
asthma population in two studies which applied the same definition of SA: 4.5% (95% CI, 280 
3.9-5.1%) (21) and 6.3% (22). The prevalence of SA in the general adult asthma 281 
population remains, however, largely uncertain since available estimates have ranged 282 
from 2.3% to 36.2% in studies that used different definitions of SA in various population- 283 
and clinic-based samples of adult asthmatics (21-26). The findings in our OA cohort 284 
further support the data reported by Lemière and coworkers (27, 28) who demonstrated 285 
that OA is associated with a higher risk of severe asthma exacerbations requiring 286 
emergency room visit or hospitalization and a greater use of healthcare resources than 287 
non-work-related asthma. Nevertheless, further studies comparing OA with asthma 288 
unrelated to work are needed to confirm the challenging hypothesis that “asthma may be 289 
more severe if it is work-related” (29). 290 
Determinants of Severe Occupational Asthma 291 
Few studies have investigated the factors that determine the severity of OA at the time of 292 
diagnosis. In a multicenter Italian study of subjects with OA confirmed by SIC, ever 293 
smoking was the only factor associated with asthma severity graded according to 294 
symptom frequency, activity limitation and lung function parameters (13). A multicenter 295 
French study found that only the duration of the symptomatic period before the diagnostic 296 
evaluation was a significant predictor of "moderate-persistent" asthma defined by the 297 
level of airway obstruction and NSBH (14).  298 
This cohort study is, to our knowledge, the first attempt to comprehensively characterize 299 
the determinants of asthma severity in a large cohort of subjects with OA using a 300 
multidimensional approach (1, 19, 20). The multivariable analyses confirmed strong 301 
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interactions between the individual dimensions of asthma severity and control (i.e., 302 
treatment level, symptom control, severe exacerbations, and airflow obstruction), similar 303 
to what has been found in general asthma populations. More specifically, poor symptom 304 
control was linked to an increased risk of severe exacerbations (5, 30, 31) and severe 305 
exacerbations were associated with greater airflow limitation (32, 33). In addition, these 306 
analyses highlighted differential effects of identified risk factors and the type of causal 307 
agent (i.e. HMW vs. LMW agents) on the individual domains of asthma severity and 308 
control, further supporting the importance of capturing separately the diverse dimensions 309 
of the disease (1, 3, 19, 20). 310 
The results of this study indicated that severe OA while exposed at work, and 311 
predominantly its high-intensity treatment component, was associated with 312 
“unchanged/persistent” exposure to the causal agent. This relationship was significant 313 
although workplace exposure was only qualitatively evaluated by the investigators as 314 
being "unchanged/persistent" or "reduced" compared with the conditions that prevailed at 315 
the time of the onset of work-related asthma symptoms. Due to the retrospective design 316 
of the study, it was not possible to quantify the duration and magnitude of exposure to 317 
“reduced” levels of causal agents. A longer duration of work-related asthma symptoms 318 
also increased the risk of severe OA, mainly through an impact on the intensity of asthma 319 
treatment and the level of airflow obstruction. Although systematic reviews of follow-up 320 
studies indicated that subjects with OA related to HMW agents are more likely to have a 321 
worse outcome after complete avoidance of exposure to the causal agent (12, 34), the 322 
risk of severe OA was not affected by the type of causal agent (i.e., LMW vs. HMW) in 323 
this cross-sectional cohort study that assessed the severity of OA at the time of diagnosis. 324 
Nevertheless, when the diverse domains of asthma severity were considered separately, 325 
subjects with OA due to LMW agents showed slightly higher rates of severe 326 
exacerbations and high-level treatment as compared to OA caused by HMW agents 327 
which is consistent with previous cross-sectional studies (35, 36). These discordant 328 
findings warrant further investigation in longitudinal studies. 329 
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In addition, the multivariable logistic regression analyses identified socio-demographic 330 
and clinical risk factors for severe OA that have been implicated in SA unrelated to work. 331 
The most clinically relevant finding in our cohort was that chronic sputum production was 332 
strongly associated with all dimensions of severe OA independently from smoking. These 333 
results are consistent with studies in adult asthmatics that documented significant 334 
associations between sputum production and uncontrolled (37) or severe (23, 26) 335 
asthma.  336 
Despite its low prevalence in this cohort, childhood asthma was a strong predictor for 337 
severe OA, especially for poor symptom control and – with borderline significance – 338 
airflow obstruction. Although atopy is a well identified risk factor for the development of 339 
OA in workers exposed to HMW agents, a history of childhood asthma was not more 340 
frequently found in severe OA caused by HMW agents (12.2%) as compared to LMW 341 
agents (11.5%). In adult asthma cohorts, the respective effects of the age at asthma 342 
onset and its duration on the severity of asthma were often not disentangled. 343 
Nevertheless, some investigators reported that an older age at asthma onset had a 344 
greater effect than asthma duration in adult asthmatics (26, 38). Interestingly, the analysis 345 
of this OA cohort indicated that both a history of childhood asthma and the duration of 346 
work-related asthma symptoms had independent effects on asthma severity through 347 
different domains.  348 
A low level of education was a significant risk factor for severe OA, mainly through a 349 
strong association with poor symptom control. Non-Caucasian ethnicity was also 350 
independently associated with poor symptom control and severe asthma exacerbations, 351 
but was not significantly associated with the multicomponent definition of severe OA. 352 
These features are likely to reflect a lower socioeconomic status which can lead to 353 
increased risk of SA through various pathways (39, 40).  354 
This OA cohort revealed several differences compared to the findings of studies 355 
conducted in general adult asthma populations. Demographic and clinical risk factors for 356 
SA that have been identified in some studies of general asthma populations, namely 357 
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female gender (41, 42), obesity (26, 42, 43); cigarette smoking (23, 26, 44, 45), rhinitis 358 
(23), and sinusitis (42, 43, 46-48) did not show an association with severe OA here 359 
although chronic sinusitis was associated with high-level treatment (Table IV). By 360 
contrast, no relationship was observed between work-related rhinitis and the severity of 361 
OA, which is discordant with the findings of Moscato and co-workers who reported that 362 
moderate-severe ocupational rhinitis was associated with more severe OA (49). However, 363 
the severity of rhinitis symptoms was not graded in our study. Of note, obesity showed a 364 
borderline significant association with severe OA but only at the time of the SIC procedure 365 
in subjects who were no longer exposed to the causal agent. This finding suggests that 366 
individual risk factors for SA may become apparent only after avoidance of the causal 367 
allergen. In this respect, OA may be regarded as a unique opportunity to investigate the 368 
factors that determine the outcome of allergic asthma after avoidance of exposure. 369 
An intriguing observation was the association between dysphonia and severe OA. 370 
Dysphonia may result from different mechanisms, including a local adverse effect from 371 
the inhalation of high doses of corticosteroids, concomitant “work-associated irritable 372 
larynx syndrome” triggered by irritants at work (50), or paradoxical vocal cord movement, 373 
which is prevalent in asthmatics with airflow obstruction and may mimic asthma 374 
symptoms (51). It is unlikely that paradoxical vocal cord movement may have led to 375 
misclassification of SA in this study since dysphonia was not associated with poor 376 
symptom control in multivariable analyses. Although there is increasing awareness of the 377 
association between upper/middle airway dysfunction and SA (51), its clinical relevance 378 
warrants further investigation. 379 
Strenghts and Limitations 380 
The strengths of this study are in its large sample size, the homogeneous diagnostic 381 
criteria used for identifying OA, and the multidimensional assessment of asthma severity 382 
(1, 3, 19, 20). However, several limitations deserve thorough discussion. Inherent to the 383 
lack of a standardized clinical assessment of workers with suspected OA among 384 
participating centers, some potential determinants of SA could not be collected, including 385 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
nonsteroidal anti-inflammatory drug sensitivity, gastro-esophageal reflux disease, 386 
psychological disorders, and magnitude of postbronchodilator FEV1 reversibility. More 387 
importantly, the level of asthma control could not be fully captured (1, 3, 19, 20) because 388 
detailed information about the frequency of daytime/nighttime symptoms and asthma-389 
related limitation of daily activities was not systematically collected. In addition, The 390 
retrospective design of the study limited our ability to distinguish severe “refractory” 391 
asthma (i.e., asthma that remains uncontrolled despite GINA treatment step 4/5) from 392 
severe “difficult-to-control” asthma (i.e., uncontrolled asthma resulting from poor 393 
adherence, poor inhalation technique, or untreated comorbidities despite follow-up by a 394 
respiratory specialist for at least 6 months) (1, 3, 19, 20). In addition, it was not possible to 395 
ascertain that the subjects were uniformly treated according to GINA guidelines and that a 396 
high-level treatment was necessay to prevent asthma from becoming uncontrolled (1). 397 
The retrospective collection of data pertaining to asthma severity and control may have 398 
have introduced some bias, especially for subjects who were no longer at work at the time 399 
of the diagnostic evaluation. 400 
We acknowledge that this multicenter cohort may not be fully representative of the whole 401 
population of workers affected with OA. The proportion of subjects with severe OA might 402 
have been overestimated because recruitment from tertiary centers could have 403 
introduced a selection bias toward subjects with more severe asthma. Conversely, the 404 
prevalence of severe OA might have been underestimated because the assessment of 405 
asthma severity was based on spirometry measurements that were available only at 406 
baseline of the SIC procedure, at a time where half the subjects had already been 407 
removed from exposure. In addition, a potential bias toward inclusion of less severe 408 
asthmatics might have occurred since most centres did not perform SIC in subjects with 409 
marked airflow obstruction (see Appendix E3 in this article’s Online Repository). However, 410 
the broad recruitment from 20 centers throughout Europe is likely to minimize as far as 411 
possible the potential selection bias due to local clinical and recruitment practices and to 412 
enhance the generalizability of the findings.  413 
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Conclusions 414 
This study shows that the determinants of severe OA include not only potentially 415 
modifiable factors (i.e. “unchanged/persistent” exposure to the causal agent and duration 416 
of symptomatic exposure before diagnosis), but also a low sociodemographic status and 417 
clinical characteristics (i.e. childhood asthma and daily sputum production). Interestingly, 418 
data collected in the subset of subjects removed from the causal agent at the time of the 419 
diagnostic evaluation suggest that the persistence of SA was predominantly driven by 420 
individual risk factors. These results further support the need for an early diagnosis and 421 
prompt implementation of environmental interventions in order to reduce the burden of 422 
severe OA. In addition, our findings may help clinicians to identify subjects with OA at 423 
high risk for a more severe outcome and contribute to a more personalized management 424 
approach aimed at minimizing the health and socioeconomic impacts of the disease.  425 
  426 
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Table I. Demographic and clinical characteristics of the subjects 473 
Characteristic Missing 
values 
All subjects 
(n=997) 
Subjects with 
severe asthma‡ 
(n=162) 
Subjects with 
non-severe 
asthma 
(n=835) 
P-value 
Age, yr* 0 42 (33-51) 44 (35-51) 42 (33-51) 0.190 
Sex (male) 0 586 (58.8) 105 (64.8) 481 (57.6) 0.100 
Body mass index:       
kg/m2 * 15 27 (24-30) 27 (24-31) 27 (24-30) 0.130 
≥30 kg/m2 15 246 (25.1) 50 (30.9) 196 (23.9) 0.070 
Smoking habits: 21    0.570 
Current smoker  195 (20.0) 36 (22.2) 159 (19.5)  
Ex-smoker  271 (27.8) 47 (29.0) 224 (27.5)  
Never-smoker  510 (52.2) 79 (48.8) 431 (53.0)  
Level of education: 144    <0.001 
Primary (≤6 years)  217 (25.4) 58 (45.7) 159 (21.9)  
Secondary (7-12 years)  562 (65.9) 62 (48.8) 500 (68.9)  
Post-secondary (>12 years)  74 (8.7) 7 (5.5) 67 (9.2)  
Ethnicity, non-Caucasian 3 60 (6.0) 18 (11.2) 42 (5.0) 0.006 
Atopy† 29 500 (51.6) 79 (51.6) 421 (51.7) 1.000 
Age of asthma onset 19    <0.001 
<12 years  46 (4.7) 19 (11.8) 27 (3.3)  
12-18 years  15 (1.5) 3 (1.9) 12 (1.5)  
>18 years  917 (93.8) 139 (86.3) 778 (95.2)  
Type of causal agent, high-molecular-weight 0 493 (49.4) 72 (44.4) 422 (50.5) 0.250 
Duration of exposure before asthma onset, mo* 16 84 (36-180) 76 (29-210) 84 (36-180) 0.800 
Duration of symptomatic exposure, mo* 12 30 (12-67) 36 (16-74) 28 (12-60) 0.020 
Interval since last work exposure and SIC, mo b 1 1.0 (0.1-8.0) 1.0 (0.1-8.8) 1.0 (0.1-7.8) 0.360 
Exposure last month at work, unchanged/persistent§ 0 762 (76.4) 138 (85.2) 624 (74.7) 0.003 
Coexisting conditions:      
Daily sputum production 16 287 (29.3) 80 (51.0) 207 (25.1) <0.001 
Work-related rhinitis 2 711 (71.5) 118 (72.8) 593 (71.2) 0.700 
Work-related conjunctivitis 14 390 (39.7) 64 (39.8) 326 (39.7) 1.000 
Chronic rhinosinusitis 8 117 (11.8) 25 (15.5) 92 (11.1) 0.140 
Dysphonia at work 40 130 (13.6) 32 (20.5) 98 (12.2) 0.010 
GINA treatment step while at work 0    <0.001 
Treatment step 0  149 (14.9) 0 149 (17.8)  
Treatment step 1  143 (14.3) 0 143 (17.1)  
Treatment step 2  57 (5.7) 0 57 (6.8)  
Treatment step 3  346 (34.7) 0 346 (41.4)  
Treatment step 4  293 (29.4) 155 (95.7) 138 (16.5)  
Treatment step 5  9 (0.9) 7 (4.3) 2 (0.2)  
Inhaled short-acting β2-agonist use while at work 0 732 (73.5) 153 (94.4) 579 (69.4) <0.001 
Never  265 (26.6) 9 (5.6) 256 (30.7)  
Once or less per week  195 (19.6) 5 (3.1) 190 (22.8)  
2 or more times a week  236 (23.7) 17 (10.5) 219 (26.2)  
≥1 times a day¥  301 (30.2) 131 (80.9) 170 (20.4)  
≥1 asthma exacerbation (last 12 mo at work) 0 232 (23.3) 77 (47.5) 155 (18.6) <0.001 
≥2 asthma exacerbation (last 12 mo at work) 0 87 (8.7) 40 (24.7) 47 (5.6) <0.001 
Work-related contact dermatitis 2 153 (15.4) 26 (16.1) 127 (15.2) 0.810 
Legend: Data are presented as n and % of available data unless otherwise specified. ICS: inhaled corticosteroid; GINA: 474 
Global Initiative for Asthma (3), SIC: specific inhalation challenge. Values in boldface are statistically significant. 475 
* Median value with interquartile range within parentheses; 476 
† Atopy defined by the presence of a positive skin-prick test to at least one common allergen; 477 
¥
 The need for a short-acting b2-agonist once or more a day was used as a proxy for “poor symptom control”; 478 
‡
 Definition of severe asthma adapted from the European Respiratory Society/American Thoracic Society criteria (1) 479 
§
 The level of exposure to the causal agent at work was qualitatively categorized by the investigators as 480 
“unchanged/persistent” or “reduced” compared to the conditions of exposure at the time of disease onset. 481 
  482 
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Table II. Functional characteristics of the subjects 483 
 
All subjects 
(n=997) 
Subjects with 
severe asthma 
(n=162) 
Subjects with 
non-severe 
asthma 
(n=835) 
P-value 
Baseline spirometry : (n=997) (n=162) (n=835)  
FVC, % pred* 99 (89-109) 94 (84-105) 100 (91-110) <0.001 
FEV1, % pred* 91 (81-100) 80 (71-93) 92 (83-101) <0.001 
FEV1 <80% 209 (21.0) 82 (50.6) 127 (15.2) <0.001 
FEV1/FVC* 77 (71-82) 70 (63-78) 77 (72-82) <0.001 
FEV1/FVC <70% 219 (22.0) 77 (47.5) 142 (17.0) <0.001 
Airflow obstruction† 119 (11.9) 65 (40.1) 54 (6.5) <0.001 
Baseline level of NSBH at the time of 
SIC¥: (n=915) (n=153) (n=762) 0.004 
Absent 259 (28.3) 28 (18.3) 231 (30.3)  
Mild 403 (44.0) 71 (46.4) 332 (43.6)  
Moderate-to-severe 253 (27.6) 54 (35.3) 199 (26.1)  
Pattern of bronchial response to SIC: (n=914) (n=155) (n=759)  
Isolated early reaction 349 (36.0) 55 (34.6) 294 (36.3) 0.720 
Isolated late reaction 226 (22.9) 33 (20.5) 193 (23.4) 0.470 
Dual reaction 339 (35.0) 67 (41.9) 272 (33.6) 0.050 
Legend: Data are presented as n (% of available data) unless otherwise specified. FEV1: forced expiratory volume 484 
in one second; FVC: forced vital capacity; NSBH: nonspecific bronchial hyperresponsiveness; SIC: specific 485 
inhalation challenge. Values in boldface are statistically significant. 486 
* Median value with interquartile range (IQR) within parentheses; 487 
†
 Airflow obstruction defined by a FEV1 <80% predicted value and a FEV1/FVC ratio <0.70; 488 
¥
 See Table E1 in this article’s Onine Repository for the threshold values used for grading the level of NSBH. 489 
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Table III. Multivariable model for severe occupational asthma while at work 491 
 492 
Independent variables 
Severe asthma* 
OR (95% CI) P-value 
Exposure-related factors: 
Low-molecular-weight causal agent, vs. high-molecular-weight  
Duration of symptomatic exposure, per 12-month periods 1.037 (1.002-1.073) 0.036 
“Unchanged/persistent” exposure at work, vs. reduced‡  2.78 (1.50-5.60) 0.002 
Socio-demographic factors: 
Age >42 yrs  
Non-Caucasian ethnicity, vs. Caucasian  
Low level of education, ≤6 yrs 2.69 (1.73-4.18) <0.001 
Clinical features: 
Childhood asthma, ≤12 yrs 2.92 (1.13-7.36) 0.024 
Daily sputum production, yes vs. no 2.86 (1.86-4.38) <0.001 
Chronic sinusitis, yes vs. no  
Dysphonia at work, yes vs. no 1.809 (1.002-3.179) 0.043 
Center-related characteristics: 
"High-activity" center (i.e. >4 positive SIC/yr), yes vs. no † 2.50 (1.16-7.08) 0.040 
Legend: 784 subjects were included in the multivariable model. An empty cell means that the independent 493 
variable was not retained in the final multivariable model and the corresponding odds ratio was not available. 494 
SIC: specific inhalation challenge. 495 
* Definition of severe asthma adapted from the European Respiratory Society/American Thoracic Society 496 
criteria (1); 497 
† The level of activity of the centers was categorized as ‘‘high’’ and ‘‘low’’ based on the median number of 498 
positive specific inhalation challenges reported annually (4.1; IQR: 2.5-7.5). 499 
‡
 The level of exposure to the causal agent at work was qualitatively categorized by the investigators as 500 
“unchanged/persistent” or “reduced” compared to the conditions of exposure at the time of disease onset. 501 
  502 
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Table IV. Multivariable models for the factors that determine the domains of asthma severity and control while at work 
 
Independent variables 
High-level treatment* Poor symptom control† Severe asthma 
exacerbations¥ Airflow obstruction
‡
 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Exposure-related factors: 
Low-molecular-agent 1.46 (1.03-2.06) 0.032  1.83 (1.03-3.31) 0.041  
Duration of symptomatic exposure 1.03 (1.00-1.06) 0.038   1.05 (1.02-1.08) 0.003 
Level of exposure, unchanged/persistent  1.79 (1.16-2.81) 0.009    
Sociodemographic factors: 
Age >42 yr     2.35 (1.50-3.73) <0.001 
Non-Caucasian ethnicity,   2.30 (1.93-4.92) 0.029 2.61 (0.98-6.45) 0.044  
Low level of education, ≤6 yr 1.40 (0.95-2.05) 0.086 2.43 (1.68-3.53) <0.001   
Clinical features: 
Childhood asthma, ≤12 yr  4.07 (1.70-10.18) 0.002  2.26 (0.94-4.96) 0.052 
Daily sputum production (yes vs. no) 1.93 (1.35-2.77) <0.001 1.62 (1.13-2.32) 0.008 1.98 (1.11-3.50) 0.019 1.62 (1.05-2.49) 0.028 
Chronic sinusitis 1.99 (1.21-3.24) 0.006    
Dysphonia at work 1.96 (1.20-3.16) 0.006    
Asthma-related factors: 
High-level treatment* NA 1.61 (1.11-2.31) 0.011 2.48 (1.41-4.37) 0.002  
Poor symptom control† 1.76 (1.20-2.57) 0.004 NA 4.46 (2.56-7.88) <0.001 1.58 (0.97 2-54) 0.060 
Exacerbation, ≥2 last 12 mo¥ 2.63 (1.50-4.61) <0.001 4.02 (2.32-7.08) <0.001 NA 2.31 (1.10-4.62) 0.021 
Center-related characteristics: 
"High-activity" center (i.e. >4 positive SIC/yr)# 1.76 (1.02-3.30) 0.054 5.21 (2.40-14.92) <0.001   
Legend: An empty cell means that the independent variable was not retained in the final multivariable model and the corresponding odds ratio was not available. NA: not applicable; SIC: specific 
inhalation challenge. 
* High-level treatment defined according Global Initiative for Asthma (GINA) as treatment step 4-5 (782 subjects were included in the multivariable model); 
† Poor symptom control defined by the use of an inhaled short-acting β2-agonist at least once a day (827 subjects were included in the multivariable model); 
¥
 Two or more severe escerbations during the last 12 months at work; severe exacerbations were defined as those requiring oral corticosteroids for at least 3 consecutive days or emergency room 
visit or hospitalization (19, 20) (780 subjects were included in the multivariable model); 
‡
 Airflow obstruction defined by a FEV1 <80% predicted value and a FEV1/FVC ratio <0.70 at the time of the SIC. Multivariable regression analysis for airway obstruction used the level of treatment 
and the need for a SABA at the time of the SIC as well as the number of exacerbations during the last 12 months before the SIC procedure (831 subjects were included in the multivariable model); 
§
 The level of exposure to the causal agent at work was qualitatively categorized by the investigators as “unchanged/persistent” or “reduced” compared to the conditions of exposure at the time of 
disease onset; 
# The level of activity of the centers was categorized as ‘‘high’’ and ‘‘low’’ based on the median number of positive specific inhalation challenges reported annually (4.1; IQR: 2.5-7.5). 
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Table V. Asthma severity at the time of the SIC in subjects removed from exposure 
(n=467) compared to the severity of their asthma while previously exposed at work  
 
Characteristic At work Off work (SIC procedure) P-value 
GINA treatment step:    
Treatment step 0 79 (16.9) 96 (20.6) 0.417 
Treatment step 1 61 (13.1) 56 (12.0)  
Treatment step 2 24 (5.1) 29 (6.2)  
Treatment step 3 151 (32.3) 154 (33.0)  
Treatment step 4 152 (32.5) 131 (28.1)  
Treatment step 5 0 1 (0.2)  
Frequency of SABA use: 332 (71.1) 286 (61.2) <0.001 
Never 135 (28.9) 181 (38.8) <0.001 
Once or less per week 73 (15.6) 146 (31.3)  
2 or more times a week 110 (23.6) 66 (14.1)  
Once or more a day* 149 (31.9)  74 (15.8)  
≥1 severe asthma exacerbations 124 (26.6)† 22 (4.7)¥ <0.001 
≥2 severe asthma exacerbations 40 (8.6)† 4 (0.9)¥ <0.001 
Severe asthma‡  84 (18.0) 52 (11.1) 0.004 
Legend: Data are presented as n and % of available data unless otherwise specified. GINA: 
Global Initiative for Asthma (3); SABA: short-acting β2-agnosit; SIC: specific inhalation 
challenge. Values in boldface are statistically significant. 
* Need for a SABA once or more a day used as a proxy for “poor symptom control”; 
† Number of exacerbations during the last 12 months of exposure at work; 
¥ Number of exacerbations during the last 12 months before the SIC procedure; 
‡ Definition of severe asthma adapted from the European Respiratory Society/American Thoracic Society 
criteria (see Methods) (1).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
 
LEGEND TO FIGURES 
FIGURE 1 
Flowchart of the study population. FEV1: forced expiratory volume in one-second; NSBH: 
nonspecific bronchial hyperresponsiveness; SIC: specific inhalation challenge (see Appendix 
E1 in this article’s Online Repository).  
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SEVERE OCCUPATIONAL ASTHMA: INSIGHTS FROM A MULTICENTER EUROPEAN 1 
COHORT 2 
ONLINE REPOSITORY MATERIAL 3 
APPENDIX E1 4 
Cohort Recruitment 5 
Twenty-four European tertiary centers performing specific inhalation challenges (SICs) for the 6 
diagnosis of occupational asthma (OA) (1) were invited to participate to this retrospective 7 
cohort, of which 20 agreed to complete the standardized database. Patient eligibility for 8 
inclusion in this cohort was based on a diagnosis of OA objectively confirmed by a positive SIC 9 
result.  10 
Nine centers reported over the full 10-year study period while 11 centers included patients with 11 
a positive SIC over periods ranging from 3 to 9 years according to available data. The median 12 
annual number of positive SICs per center was 4.1 (interquartile range, 2.5-7.5). 13 
For each subject entered in the database, investigators were asked to provide the maximum fall 14 
in forced expiratory volume in 1 second (FEV1) expressed as percent from baseline value that 15 
was recorded after the end of the challenge exposure as well as the level of nonspecific 16 
bronchial hyperresponsiveness (NSBH) measured before the SIC and 24 hours after the end of 17 
challenge exposure (see below “Assessment of nonspecific bronchial hyperresponsiveness”). A 18 
positive SIC result was defined by either a ≥15% fall in FEV1 at any time-point during the post-19 
challenge monitoring period or a significant increase in the post-challenge level of NSBH as 20 
compared to the baseline value (2-4).  21 
One thousand one hundred eighty of the 1,249 reported subjects had either a documented 22 
≥15% fall in FEV1 during SIC (n=1,105) or a significant increase in the post-challenge level of 23 
NSBH in the absence of a ≥15% fall in FEV1 (n=75). Of these 1,180 eligible subjects, 183 were 24 
excluded from analysis because of incomplete information on asthma medications (n=89), 25 
asthma exacerbations (n=97), and/or baseline spirometry (n=5), which were considered key 26 
variables for this analysis. The final cohort included 997 analyzable subjects. 27 
Data Collection 28 
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Detailed information on demographic, clinical, occupational, and physiological characteristics of 29 
the subjects at the time of the diagnostic evaluation were entered in a standardized Excel 30 
database in each participating center by local investigators (see Appendix E1 and in this 31 
article’s Online Repository). The requested information was exclusively retrieved from medical 32 
charts in 10 centers while in the other centers, all or part of the data had been prospectively 33 
entered in existing local databases. The standardized databases were then checked by three 34 
investigators (OV, CR, and JD), pooled together and centralized at the Strasbourg University 35 
(FdB, NM, and JG).  36 
  37 
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APPENDIX E2 38 
Assessment of Nonspecific Bronchial Hyperresponsiveness 39 
The database collected information on the level of NSBH measured at baseline and 24 hours 40 
after the end of challenge exposure. The level of NSBH was expressed as the concentration or 41 
dose of the pharmacological agent inducing a 15% or 20 % fall in FEV1 (PC/PD15-20%) according 42 
to the bronchoprovocation method used in each center. Since participating centers used six 43 
different methods, the level NSBH was only categorized as “absence of NSBH”, “mild NSBH”, 44 
and “moderate-to-severe NSBH” based on available recommendations (5-7) or using a 45 
consensus Delphi approach among investigators. The bronchoprovocation methods and 46 
threshold values used for defining the level of NSBH are detailed in Table E2. Overall, NSBH 47 
was not assessed in 82 of 997 subjects. Among these subjects, the diagnosis of asthma was 48 
documented by reversible airflow obstruction on spirometry (n=37) or daily variations in peak 49 
expiratory flow (n=30). The diagnosis of asthma was not formally documented in 15 subjects. A 50 
significant increase in post-challenge level of NSBH was defined as a ≥2-fold decrease in the 51 
PC/PD15-20% value recorded 24 hours after the challenge exposure as compared to the baseline 52 
value (i.e. a pre/post PC/PD15-20% ratio ≥2) (2-4). 53 
  54 
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APPENDIX E3 55 
Methodology of Specific Inhalation Challenges 56 
Participating investigators completed a questionnaire in order to evaluate whether: 1) a control 57 
(placebo) test was performed before challenging the subjects with the suspected occupational 58 
agent(s) and 2) a functional monitoring of at least 6 hours after the end of challenge exposures 59 
was completed in order to ensure compliance with international recommendations (4, 5). They 60 
were also requested to state which lower limit value of FEV1 they considered a contra-indication 61 
for performing a SIC procedure. This lower limit of FEV1 was 70% of predicted value in 11 62 
centers, 65% in one center; 60% in six centers, and 50% in 2 centers.  63 
Asthma medications were adapted according to the Global Initiative for Asthma guidelines in 64 
subjects who showed increased variability in FEV1 or peak expiratory flow rates before the SIC 65 
procedure or during the control day. Long-acting and short-acting bronchodilators were stopped 66 
before the SIC according to their duration of action. Inhaled corticosteroids were withdrawn for 67 
two to seven days before the SIC procedure in 18 centers and for longer periods (i.e. at least 15 68 
days or 28 days) in two centers. However, the daily dose of inhaled corticosteroids could be 69 
administered as a single evening dose during the SIC procedure in subjects whose asthma 70 
became unstable after inhaled corticosteroids withdrawal.  71 
For each specific inhalation challenge (SIC), the database requested information on the method 72 
used for delivering the suspected occupational either through a “realistic” approach mimicking 73 
the workplace exposure (n=944) (8) or the inhalation an “allergen extract” (n=53). A detailed 74 
description of the methods used for delivering various occupational agents during SICs has 75 
been compiled by the European Taskforce on SIC from twelve specialist centers participating to 76 
the current cohort study (4). This “Handbook of procedures for specific inhalation challenge 77 
testing in the diagnosis of occupational asthma” is available from www.erj.ersjournals.com as 78 
an online supplementary material to the European Respiratory Society consensus statement on 79 
specific inhalation challenge in the diagnosis of occupational asthma (4). 80 
The database collected the maximum fall in FEV1 expressed as percent from baseline value 81 
that was recorded during two distinct time periods of the post-challenge functional monitoring: 82 
1) the period between the end of the challenge exposure and the 60th minute post-exposure 83 
(i.e. the “early component” of the bronchial response) and 2) the period between the 60th 84 
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minute post-challenge and the end of the post-SIC follow-up (i.e. the “late component” of the 85 
bronchial response). 86 
The results of the SICs were interpreted a posteriori according to standardized criteria (4). A 87 
positive SIC result was defined by either a ≥15% fall in FEV1 at any time during the post-88 
challenge monitoring or a twofold or greater increase in the post-challenge level of NSBH in the 89 
absence of significant changes in FEV. Among the 997 subjects included in this analysis, 935 90 
subjects showed a ≥15% fall in FEV1 during SIC and 62 a significant increase in the post-91 
challenge level of NSBH. 92 
  93 
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APPENDIX E4 94 
Statistical Analysis 95 
Multivariable logistic regression analysis was carried out using a binomial generalized linear 96 
model to identify the clinical and physiological characteristics that were significantly and 97 
independently associated with severe OA. The potential explanatory variables incorporated into 98 
these regressions were selected based on bivariate exploratory analyses and potential risk 99 
factors for SA identified in the literature. The model consisted of the following variables: age 100 
(>42 yr vs. ≤42 yr); sex; ethnicity (Caucasian vs. non-Caucasian); body mass index (BMI, ≥30 101 
kg/m2 vs. <30 kg/m2; atopy (presence vs. absence of a positive skin-prick test response to at 102 
least one common aeroallergen); smoking status (never vs ever being a smoker); level of 103 
education (≤6 yr vs. >6 yr); age at asthma onset (<12 yr vs. ≥12 yr); type of causal agent (low-104 
molecular-weight [LMW] vs. high-molecular-weight [HMW] agent); duration of asthma 105 
symptoms at work; level of exposure during the last month at work (persistently high vs. 106 
reduced); work-related rhinitis or conjunctivitis (yes vs. no); daily sputum production (yes vs. 107 
no); chronic sinusitis (yes vs. no); dysphonia at work (yes vs. no); and recruitment from a center 108 
with a “high-activity” (i.e., >4 positive SICs per year) vs. a “low-activity” (i.e. ≤4 positive SICs 109 
per). The various components of asthma severity (i.e. high-intensity treatment; poor symptom 110 
control; ≥2 severe exacerbations during the last 12 months at work; and airflow obstruction) 111 
were not included in this analysis because they are part of the definition of severe asthma. 112 
Model selection was performed on this dataset with removed missing values using a stepwise 113 
algorithm (both forward and backward stepwise searches) based on Akaike information criterion 114 
(AIC) (stepAIC function in the MASS package). This procedure selects the most parsimonious 115 
model with informative variables. Odds ratio (and CI) are reported for each variable retained in 116 
the final model. Missing values were not imputed.  117 
Additional multivariable logistic regressions were conducted in order to identify the variables 118 
associated with each of the domains used to define SA while at work: high-intensity treatment 119 
(i.e. GINA treatment step 4-5); poor symptom control (i.e. SABA ≥1/day); ≥2 severe 120 
exacerbations during the last 12 months at work; and airflow obstruction. The same 121 
independent variables as those used in the multivariable analysis of severe OA were included 122 
into these logistic regressions and the best models were selected based on AIC. The severity 123 
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domains were also included as independent variables in the models where appropriate, but 124 
airway obstruction was not included since spirometric values were those measured at the time 125 
of the SIC procedure when 46.8% of the study subjects where already removed from exposure. 126 
Likewise, the level of treatment and the need for a SABA at the time of the SIC procedure, and 127 
the number of exacerbations during the last 12 months before the SIC were used in the 128 
multivariable regression analysis of airway obstruction in order to take into account the potential 129 
effect of cessation of exposure in a substantial fraction of the subjects.   130 
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Table E1. Methods used for measuring the level of nonspecific bronchial 131 
hyperresponsiveness 132 
 133 
Method (pharmacological 
agent) 
No. of 
centers 
(subjects) 
Threshold values for nonspecific bronchial 
hyperresponsiveness 
Moderate-to-
severe 
Mild Absent 
Tidal breath method 
(histamine/methacholine) 
(5, 6) 
5 (404) PC20 <1 mg/ml PC20: 1-16 mg/ml PC20 >16 mg/ml 
Five-breath dosimeter method 
(methacholine) 
(5, 6) 
9 (257) PD20 <0.1 mg 
PC20 <1 mg/ml 
PD20: 0.1-1.5 mg 
PC20: 1-16 mg/ml 
PD20 >1.5 mg 
PC20 >16 mg/ml 
Rapid dosimeter method  
(histamine) 
(7) 
2 (185)  PD15 <0.4 mg  PD15: 0.4-1.6 mg  PD15 >1.6 mg  
APS dosimeter method 
(histamine/methacholine) 
(9) 
2 (66) PD20<0.1 mg 
PC20 <1 mg/ml 
PD20: 0.1-1.4 mg 
PC20: 1-16 mg/ml 
PD20 <1.4 mg 
PC20 >16 mg/ml 
Reservoir bag dosimeter method 
(methacholine) 
(10) 
1 (2) PD20 or PD100sRt 
<0.1 mg 
PD20 or PD100 sRt: 
0.1-0.3 mg 
PD20 or PD100sRt 
>0.3 mg 
Dosimeter method 
(mannitol) 
(11) 
1(1) PD15 ≤250 mg  PD15: 251-635 mg  PD15 >635 mg  
Legend: PC/PD15/20: provocative concentration of pharmacological agent inducing a 15 or 20% fall in 134 
forced expiratory volume in 1 s (FEV1); PD100 sRt: provocative concentration of pharmacological agent 135 
inducing a doubling of specific airway resistance. 136 
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Table E2. Causal agents 138 
 139 
High-molecular-weight agents n (%)* Low-molecular-weight agents n (%)* 
Flour/grains 341 (34.6) Isocyanates 139 (14.1) 
Latex 35 (3.6) Persulfate salts 57 (5.8) 
Enzymes 23 (2.3) Quaternary ammonium compounds 38 (3.9) 
Storage mites 10 (1.0) Metals 30 (3.0) 
Cow dander 9 (0.9) Welding 30 (3.0) 
Rodents 9 (0.9) Wood dusts 28 (2.8) 
Fish/seafood 8 (0.8) Acrylate compounds 28 (2.8) 
Ornemental plants 6 (0.6) Cleaning products/disinfectant (NOS) 26 (2.6) 
Insects and derived products 5 (0.5) Aldehydes 15 (1.5) 
Vegetal gums 3 (0.3) Metal working fluids 15 (1.5) 
Soybean flour 3 (0.3) Resins/glues/paints (NOS) 15 (1.5) 
Spices 3 (0.3) Epoxy resins 14 (1.4) 
Moulds 2 (0.2) Amines 10 (1.0) 
Various plant-derived products 22 (2.2) Acid anhydrides 10 (1.0) 
Various animals and derived products 14 (1.4) Drugs 9 (0.9) 
  Colophony 4 (0.4) 
  Reactive dyes 2 (0.2) 
  Styrene 2 (0.2) 
  Triglycidylisocyanurate 1 (0.1) 
  Various low-molecular-weight agents 17 (1.7) 
Total: 493 (50.1) Total: 492 (49.9) 
Legend: NOS: not otherwise specified 140 
* % of total identified agents (n=985); the causal agent was not precisely identified in 12 subjects. 141 
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